Research progress on the epidemic status, diagnosis, treatment and control measures of Chikungunya fever

doi:10.20199/j.issn.1672-2302.2026.01.011

Abstract

Abstract:

Chikungunya fever is an acute mosquito-borne infection caused by the Chikungunya virus and transmitted by Aedes mosquitoes. To date, the disease has been reported in 119 countries and regions worldwide. Imported cases have been recorded in 16 provinces (autonomous regions and municipalities) in China. The important clinical manifestations of this infection include sudden onset of fever, skin rash, and joint pain, while some patients may experience atypical symptoms such as neurological involvement. As the disease is generally infectious to the population, and vaccines have not yet been widely administered worldwide, prevention and control of it mainly rely on comprehensive preventive measures in current stage. This article reviews the etiological characteristics, global epidemiology, epidemic process, clinical manifestations, diagnosis and treatment, and prevention and control strategies of Chikungunya fever, with an attempt to provide references for responding to its spread and outbreaks.

Key words: Chikungunya fever, Epidemiological characteristics, Clinical manifestations, Diagnosis, Treatment, Preventive and control measures

CLC Number:

R512.8，R181.3

ZHANG Liqin, GONG Lei, LIU Yaqian, DAI Yanni, GENG Haoxiang, MENG Meng, WU Jiabing. Research progress on the epidemic status, diagnosis, treatment and control measures of Chikungunya fever[J]. Journal of Tropical Diseases and Parasitology, 2026, 24(1): 58-64.

References 89

[1]	Bartholomeeusen K, Daniel M, LaBeaud DA, et al. Chikungunya fever[J]. Nat Rev Dis Primers, 2023, 9:17. doi: 10.1038/s41572-023-00429-2 pmid: 37024497
[2]	Vairo F, Haider N, Kock R, et al. Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention[J]. Infect Dis Clin North Am, 2019, 33(4):1003-1025. doi: 10.1016/j.idc.2019.08.006 URL
[3]	Ning XH, Xia BH, Wang JQ, et al. Host-adaptive mutations in Chikungunya virus genome[J]. Virulence, 2024, 15(1):2401985. doi: 10.1080/21505594.2024.2401985 URL
[4]	Tsetsarkin KA, Vanlandingham DL, McGee CE, et al. A single mutation in chikungunya virus affects vector specificity and epidemic potential[J]. PLoS Pathog, 2007, 3(12):e201. doi: 10.1371/journal.ppat.0030201 pmid: 18069894
[5]	Schuffenecker I, Iteman I, Michault A, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak[J]. PLoS Med, 2006, 3(7):e263. doi: 10.1371/journal.pmed.0030263 pmid: 16700631
[6]	Fu YF, Li SB, Zhang Z, et al. Phylogeographic analysis of severe fever with thrombocytopenia syndrome virus from Zhoushan Islands, China: implication for transmission across the ocean[J]. Sci Rep, 2016, 6:19563. doi: 10.1038/srep19563 pmid: 26806841
[7]	Tan Y, Pickett BE, Shrivastava S, et al. Differing epidemiological dynamics of Chikungunya virus in the Americas during the 2014-2015 epidemic[J]. PLoS Negl Trop Dis, 2018, 12(7):e0006670. doi: 10.1371/journal.pntd.0006670 URL
[8]	Liu LB, Li M, Gao N, et al. Epidemiological and clinical characteristics of the chikungunya outbreak in Ruili City, Yunnan Province, China[J]. J Med Virol, 2022, 94(2):499-506. doi: 10.1002/jmv.v94.2 URL
[9]	Pan JH, Fang CF, Yan JY, et al. Chikungunya fever outbreak, Zhejiang Province, China, 2017[J]. Emerg Infect Dis, 2019, 25(8):1589-1591. doi: 10.3201/eid2508.181212 pmid: 31310205
[10]	Wu D, Wu J, Zhang QL, et al. Chikungunya outbreak in Guangdong Province, China, 2010[J]. Emerg Infect Dis, 2012, 18(3):493-495. doi: 10.3201/eid1803.110034 pmid: 22377135
[11]	Zhang Y, Zhuo ZP, Huang YP, et al. Genomic characterization and evolutionary analysis of Chikungunya virus strains in Guangzhou, China, 2025[J]. Virol J, 2025, 23(1):15. doi: 10.1186/s12985-025-03051-8
[12]	Manimunda SP, Sugunan AP, Rai SK, et al. Outbreak of chikungunya fever, dakshina Kannada district, south India, 2008[J]. Am J Trop Med Hyg, 2010, 83(4):751-754. doi: 10.4269/ajtmh.2010.09-0433 URL
[13]	Leo YS, Chow ALP, Tan LK, et al. Chikungunya outbreak, Singapore, 2008[J]. Emerg Infect Dis, 2009, 15(5):836-837. doi: 10.3201/eid1505.081390 pmid: 19402989
[14]	Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region[J]. Lancet, 2007, 370(9602):1840-1846. doi: 10.1016/S0140-6736(07)61779-6 pmid: 18061059
[15]	Gould EA, Gallian P, De Lamballerie X, et al. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality![J]. Clin Microbiol Infect, 2010, 16(12):1702-1704. doi: 10.1111/j.1469-0691.2010.03386.x URL
[16]	Dupont-Rouzeyrol M, Caro V, Guillaumot L, et al. Chikungunya virus and the mosquito vector Aedes aegypti in New Caledonia (South Pacific Region)[J]. Vector Borne Zoonotic Dis, 2012, 12(12):1036-1041. doi: 10.1089/vbz.2011.0937 pmid: 23167500
[17]	Cassadou S, Boucau S, Petit-Sinturel M, et al. Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013[J]. Euro Surveill, 2014, 19(13):20752.
[18]	Fischer M, Staples JE. Notes from the field: chikungunya virus spreads in the Americas-Caribbean and South America,2013-2014[J]. Morb Mortal Wkly Rep, 2014, 63(22):500-501.
[19]	de Souza WM, Ribeiro GS, de Lima STS, et al. Chikungunya: a decade of burden in the Americas[J]. Lancet Reg Health Am, 2024, 30:100673.
[20]	World Health Organization. Chikungunya epidemiology update-June 2025[EB/OL]. (2025-06-11)[2025-08-01]. https://www.who.int/publications/m/item/chikungunyaepidemiology-update-june-2025.
[21]	韩辉, 伍波, 周奇. 2025年3月全球传染病疫情研判分析[J]. 疾病监测, 2025, 40(4):414-416.
[22]	韩辉, 伍波, 周奇,等. 2025年9月全球传染病疫情研判分析[J]. 疾病监测, 2025, 40(10):1244-1246.
[23]	张海林, 施华芳, 刘丽华,等. 从云南省蝙蝠中分离基孔肯雅病毒及血清抗体调查[J]. 病毒学报, 1989, 5(1):31-36.
[24]	施华芳, 张海林, 自登云,等. 云南首次从患者体内分离到基孔肯雅病毒[J]. 中国人兽共患病杂志, 1990(1):2-4.
[25]	林苗, 李华, 黄吉城,等. 广东检验检疫局发现中国内地首例输入性基孔肯雅热病例[J]. 中国国境卫生检疫杂志, 2008, 31(4):221-223,236.
[26]	黄仁杰, 谢立, 缪凡,等. 杭州发现1例输入性基孔肯雅热病例[J]. 疾病监测, 2009, 24(4):303.
[27]	袁达康, 黄勇, 陈平华. 我国首起基孔肯雅热社区暴发疫情的流行病学调查分析[C]// 中华医学会医学病毒学分会,广东省预防医学会医学病毒学专业委员会,广东省免疫学会. 新发和再发传染病防治热点研讨会论文集. 东莞: 东莞市疾病预防控制中心,2011:100-103.
[28]	曹国平, 钟建跃, 郑灿杰, 等. 中国第二起基孔肯雅热暴发疫情调查结果分析[C]// 浙江省医学会热带病与寄生虫病分会. 2018年浙江省医学会热带病与寄生虫病学术年会论文汇编. 衢州: 衢州市疾病预防控制中心,2018:28-35.
[29]	尹小雄, 刘永华, 张海林,等. 2019年云南中缅边境基孔肯雅热暴发疫情的流行病学特征[J]. 中华实验和临床病毒学杂志, 2020, 34(6):600-604.
[30]	陈斌, 陈秋兰, 李昱,等. 2010—2019年中国输入性基孔肯雅热病例流行病学特征分析[J]. 疾病监测, 2021, 36(6):539-543.
[31]	Tee KK, Mu DK, Xia XS. Explosive chikungunya virus outbreak in China[J]. Int J Infect Dis, 2025, 161:108089. doi: 10.1016/j.ijid.2025.108089 URL
[32]	文海燕, 骆星丹, 王董,等. 重庆口岸首次检出的基孔肯雅病毒全基因组序列特征[J]. 中国国境卫生检疫杂志, 2023, 46(4):313-315.
[33]	单永业, 陈乙松, 黄金妹,等. 海口市首例输入性基孔肯雅热病例报告[J]. 中国热带医学, 2025, 25(12):1637-1640. doi: 10.13604/j.cnki.46-1064/r.2025.12.20
[34]	李双玲, 朱鑫. 河南省首例基孔肯雅热病例流行性学调查报告[J]. 河南预防医学杂志, 2019, 30(4):328-330.
[35]	高玉峰, 侯丽, 傅韶瑜,等. 大连口岸首例输入性基孔肯雅热病例的实验室检测和确认[J]. 中国国境卫生检疫杂志, 2021, 44(5):309-310,334.
[36]	张海林, 自登云, 米竹青,等. 云南白纹伊蚊分布特点及与虫媒病毒的关系[J]. 中国媒介生物学及控制杂志, 2001, 12(2):103-105.
[37]	Vega-Rúa A, Zouache K, Girod R, et al. High level of vector competence of Aedes aegypti and Aedes albopictus from ten American countries as a crucial factor in the spread of Chikungunya virus[J]. J Virol, 2014, 88(11):6294-6306. doi: 10.1128/JVI.00370-14 pmid: 24672026
[38]	Agarwal A, Dash PK, Singh AK, et al. Evidence of experimental vertical transmission of emerging novel ECSA genotype of Chikungunya virus in Aedes aegypti[J]. PLoS Negl Trop Dis, 2014, 8(7):e2990. doi: 10.1371/journal.pntd.0002990 URL
[39]	Economopoulou A, Dominguez M, Helynck B, et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion[J]. Epidemiol Infect, 2009, 137(4):534-541. doi: 10.1017/S0950268808001167 pmid: 18694529
[40]	Appassakij H, Silpapojakul K, Promwong C, et al. The potential impact of chikungunya virus outbreaks on blood transfusion[J]. Transfus Med Rev, 2020, 34(1):23-28. doi: S0887-7963(17)30190-6 pmid: 31303361
[41]	da Silva Mendes AM, Cilião-Alves DC, Pimentel BMS, et al. Chikungunya virus seroprevalence in asymptomatic blood donors during an outbreak in the Federal District of Brazil[J]. Transfus Med, 2022, 32(4):338-342. doi: 10.1111/tme.v32.4 URL
[42]	Babu N N, Jayaram A, Shetty U, et al. Clinical and molecular epidemiology of chikungunya outbreaks during 2019-2022 in India[J]. Sci Rep, 2025, 15(1):27280. doi: 10.1038/s41598-025-09771-9
[43]	梁运光, 谢周华, 黎彦君,等. 50例基孔肯雅热患者的流行病学及临床特征分析[J]. 广西医学, 2025, 47(10):1450-1453.
[44]	Liu Q, Shen H, Gu L, et al. Chikungunya virus in Europe: a retrospective epidemiology study from 2007 to 2023[J]. PLoS Negl Trop Dis, 2025, 19(3):e0012904. doi: 10.1371/journal.pntd.0012904 URL
[45]	Li YH, Jiang SY, Zhang M, et al. An outbreak of chikungunya fever in China-Foshan City, Guangdong Province, China, July 2025[J]. China CDC Wkly, 2025, 7(32):1064-1065.
[46]	Khongwichit S, Chuchaona W, Korkong S, et al. Chikungunya virus in Thailand (2020-2023): Epidemiology, clinical features, and genomic insights[J]. PLoS Negl Trop Dis, 2025, 19(9):e0013548. doi: 10.1371/journal.pntd.0013548 URL
[47]	de Andrade GC, Ventura CV, de Arruda Mello Filho PA, et al. Arboviruses and the eye[J]. Int J Retina Vitreous, 2017, 3(1):4. doi: 10.1186/s40942-016-0057-4 URL
[48]	Chiu CY, Bres V, Yu GX, et al. Genomic assays for identification of chikungunya virus in blood donors, Puerto Rico, 2014[J]. Emerg Infect Dis, 2015, 21(8):1409-1413. doi: 10.3201/eid2108.150458 pmid: 26196378
[49]	Nakkhara P, Chongsuvivatwong V, Thammapalo S. Risk factors for symptomatic and asymptomatic chikungunya infection[J]. Trans R Soc Trop Med Hyg, 2013, 107(12):789-796. doi: 10.1093/trstmh/trt083 URL
[50]	de Jesus Pereira B, Brasil MQA, de Jesus Silva J, et al. Chikungunya in a pediatric cohort: Asymptomatic infection, seroconversion, and chronicity rates[J]. PLoS Negl Trop Dis, 2025, 19(7):e0013254. doi: 10.1371/journal.pntd.0013254 URL
[51]	Bustos Carrillo F, Collado D, Sanchez N, et al. Epidemiological evidence for lineage-specific differences in the risk of inapparent chikungunya virus infection[J]. J Virol, 2019, 93(4):e01622-e01618.
[52]	Yoon IK, Alera MT, Lago CB, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines[J]. PLoS Negl Trop Dis, 2015, 9(5):e0003764. doi: 10.1371/journal.pntd.0003764 URL
[53]	Benjamanukul S, Osiri M, Chansaenroj J, et al. Rheumatic manifestations of Chikungunya virus infection: Prevalence, patterns, and enthesitis[J]. PLoS One, 2021, 16(4):e0249867. doi: 10.1371/journal.pone.0249867 URL
[54]	O’Driscoll M, Salje H, Chang AY, et al. Arthralgia resolution rate following chikungunya virus infection[J]. Int J Infect Dis, 2021, 112:1-7. doi: 10.1016/j.ijid.2021.08.066 pmid: 34492392
[55]	Tritsch SR, Encinales L, Pacheco N, et al. Chronic joint pain 3 years after chikungunya virus infection largely characterized by relapsing-remitting symptoms[J]. J Rheumatol, 2020, 47(8):1267-1274. doi: 10.3899/jrheum.190162 pmid: 31263071
[56]	Sissoko D, Malvy D, Ezzedine K, et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period[J]. PLoS Negl Trop Dis, 2009, 3(3):e389. doi: 10.1371/journal.pntd.0000389 URL
[57]	Rollé A, Schepers K, Cassadou S, et al. Severe sepsis and septic shock associated with chikungunya virus infection, Guadeloupe, 2014[J]. Emerg Infect Dis, 2016, 22(5):891-894. doi: 10.3201/eid2205.151449 pmid: 27088710
[58]	Tandale BV, Sathe PS, Arankalle VA, et al. Systemic involvements and fatalities during Chikungunya epidemic in India, 2006[J]. J Clin Virol, 2009, 46(2):145-149. doi: 10.1016/j.jcv.2009.06.027 pmid: 19640780
[59]	Pedí VD, Porto DL, de Jesus Martins W, et al. Brazil, Epidemiology of chikungunya hospitalizations,2014-2024[J]. Emerg Infect Dis, 2025, 31(9):1718-1728.
[60]	de Souza WM, Fumagalli MJ, de Lima STS, et al. Pathophysiology of chikungunya virus infection associated with fatal outcomes[J]. Cell Host Microbe, 2024, 32(4):606-622, e8. doi: 10.1016/j.chom.2024.02.011 pmid: 38479396
[61]	Cabral-Castro MJ, Cavalcanti MG, Peralta RHS, et al. Molecular and serological techniques to detect co-circulation of DENV, ZIKV and CHIKV in suspected dengue-like syndrome patients[J]. J Clin Virol, 2016, 82:108-111. doi: S1386-6532(16)30187-1 pmid: 27479173
[62]	Bonifay T, Vesin G, Bidaud B, et al. Clinical characteristics and predictive score of dengue vs. chikungunya virus infections[J]. Med Mal Infect, 2019, 49(4):250-256. doi: 10.1016/j.medmal.2018.09.010 URL
[63]	Wan SC, Zhang X, Cong X, et al. Viral load dynamics of chikungunya virus in human specimens-Foshan City, Guangdong Province, China, 2025[J]. China CDC Wkly, 2025, 7(33):1067-1072.
[64]	国家卫生健康委办公厅, 国家中医药局综合司. 关于印发基孔肯雅热诊疗方案(2025 年版)的通知:国卫办医急函〔2025〕328号[A/OL]. [2025-08-11]. https://www.nhc.gov.cn/ylyjs/gzdt/202507/c592a4f82dd7405e9be5302e4147c0c7.shtml.
[65]	陈广, 巩维进, 马科,等. 重症基孔肯雅热诊治专家共识[J]. 内科急危重症杂志, 2025, 31(5):385-394.
[66]	卢诗颖, 郑丹文, 洪新田,等. 基于横断面调查的基孔肯雅热患者中医证候特征研究[J]. 北京中医药大学学报, 2025, 48(11):1531-1539.
[67]	周克梅, 杨明东, 兰学梅,等. 云南省129个县(市、区)主城区登革热媒介伊蚊分布调查[J]. 中国媒介生物学及控制杂志, 2021, 32(2):150-157. doi: 10.11853/j.issn.1003.8280.2021.02.006
[68]	Sim S, Ng LC, Lindsay SW, et al. A greener vision for vector control: The example of the Singapore dengue control programme[J]. PLoS Negl Trop Dis, 2020, 14(8):e0008428. doi: 10.1371/journal.pntd.0008428 URL
[69]	崔鹏, 谢丹, 郑国林. 樟树市一起登革热暴发疫情流行特征及防控情况剖析[J]. 安徽预防医学杂志, 2023, 29(2):164-167.
[70]	Gopalan RB, Babu BV, Sugunan AP, et al. Community engagement to control dengue and other vector-borne diseases in Alappuzha municipality, Kerala, India[J]. Pathog Glob Health, 2021, 115(4):258-266. doi: 10.1080/20477724.2021.1890886 URL
[71]	王英. 我国蚊媒防制策略及成就和挑战[J]. 中国热带医学, 2019, 19(9):807-811. doi: 10.13604/j.cnki.46-1064/r.2019.09.01
[72]	兰学梅, 魏春, 朱进,等. 中国-老挝登革热重点地区埃及伊蚊孳生习性及杀虫剂抗性水平比较研究[J]. 中国媒介生物学及控制杂志, 2023, 34(2):238-243. doi: 10.11853/j.issn.1003.8280.2023.02.016
[73]	李雪, 凌峰, 屈志强,等. 南宁市2022—2024年白纹伊蚊对常用杀虫剂的抗药性监测[J]. 中国热带医学, 2025, 25(6):761-764. doi: 10.13604/j.cnki.46-1064/r.2025.06.14
[74]	Moro ML, Gagliotti C, Silvi G, et al. Chikungunya virus in North-Eastern Italy: a seroprevalence survey[J]. Am J Trop Med Hyg, 2010, 82(3):508-511. doi: 10.4269/ajtmh.2010.09-0322 URL
[75]	Eba K, Duchateau L, Olkeba BK, et al. Bio-control of Anopheles mosquito larvae using invertebrate predators to support human health programs in Ethiopia[J]. Int J Environ Res Public Health, 2021, 18(4):1810. doi: 10.3390/ijerph18041810 URL
[76]	Hussain M, Zhang GM, Leitner M, et al. Wolbachia RNase HI contributes to virus blocking in the mosquito Aedes aegypti[J]. iScience, 2023, 26(1):105836. doi: 10.1016/j.isci.2022.105836 URL
[77]	Macedo AT, Carvalho DO, Gomez M, et al. Field implementation of the sterile insect technique against Aedes aegypti in Recife, Brazil: operational challenges and impact of release frequency on vector dynamics[J]. Infect Dis Poverty, 2026, 15(1):16. doi: 10.1186/s40249-025-01393-7
[78]	陈德华, 周泰霖, 叶晓磊,等. 几种驱避剂对埃及伊蚊驱避效果的研究[J]. 中华卫生杀虫药械, 2018, 24(6):539-541.
[79]	周楚楚, 何鸿阳, 刘静,等. 16种市售驱蚊产品对白纹伊蚊驱避效果比较[J]. 绵阳师范学院学报, 2024, 43(11):68-74.
[80]	杨维芳, 褚宏亮, 徐燕. 我国基孔肯雅热流行现状及媒介伊蚊控制研究进展[J]. 江苏预防医学, 2025, 36(5):529-532.
[81]	陈凤灵, 邵昭明, 梁超斌, 等. 佛山市禅城区创建登革热综合防控示范区居民健康教育干预效果评价[J]. 华南预防医学, 2017, 43(2):150-153.
[82]	徐旭雯, 蔡少航, 莫希超, 等. 当前我国基孔肯雅热防控的挑战和应对措施[J]. 新发传染病电子杂志, 2025, 10(4):1-6,113. doi: 10.19871/j.cnki.xfcrbzz.2025.04.001
[83]	Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4 pmid: 37321235
[84]	Richardson JS, Anderson DM, Mendy J, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2025, 405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9 URL
[85]	Tindale LC, Richardson JS, Anderson DM, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2025, 405(10487):1353-1361. doi: 10.1016/S0140-6736(25)00372-1 URL
[86]	Simone B, Lienert F. Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025[J]. Euro Surveill, 2025, 30(44):2500792.
[87]	Folegatti PM, Harrison K, Preciado-Llanes L, et al. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial[J]. Nat Commun, 2021, 12(1):4636. doi: 10.1038/s41467-021-24906-y pmid: 34330906
[88]	Reisinger EC, Tschismarov R, Beubler E, et al. Immunogenicity,safety,and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial[J]. Lancet, 2019, 392(10165):2718-2727. doi: S0140-6736(18)32488-7 pmid: 30409443
[89]	王刚, 缪志江, 夏雪山. 中国基孔肯雅病毒的境外输入风险及应对策略[J]. 昆明理工大学学报(自然科学版), 2022, 47(6):87-92,107.